Chronic opiate abuse accelerates the development of cognitive deficits in human immunodeficiency virus (HIV)-1 patients. To investigate morphine's effects on viral infection of the central nervous system, we applied chronic morphine treatment to the LP-BM5 murine acquired immunodeficiency syndrome (MAIDS) model. LP-BM5 infection induces proinflammatory cytokine/chemokine production, correlating to increased bloodbrain barrier permeability. Morphine treatment significantly increased LP-BM5 viral load in the hippocampus, but not in the frontal lobe. Morphine reduced the chemokine CCL5 to non-infected levels in the frontal lobe, but not in the hippocampus. These data indicate a region-specific mechanism for morphine's effects on virallyinduced neurocognitive deficits.
Introduction
Nearly one-third of the 35 million people living with human immunodeficiency virus (HIV) infection worldwide will develop symptoms of HIV-associated neurocognitive disorder (HAND) (McArthur, 2004; UNAIDS, 2013) . While improved antiretroviral therapies have reduced dementia rates to~1% of the total HIV-positive population, milder HAND deficits including motor and cognitive impairment have not declined (McArthur, 2004; Yadav and Collman, 2009 ). Heroin and its active metabolite, morphine, accelerate disease progression into acquired immunodeficiency syndrome (AIDS) and increase both the risk and severity of HAND (Bell et al., 1998; Nath et al., 2002; McArthur, 2004; Robertson et al., 2007) . With up to one-third of HIVpositive patients reporting opiate abuse, the interaction between morphine and HAND represents a serious concern in long-term HIV care (Bell et al., 1998; UNAIDS, 2013) . However, the mechanism for morphine's effects on central nervous system (CNS) infection and neurological damage in HIV-1 infected patients remains controversial.
The CNS defends against viral infection through i) the blood-brain barrier (BBB), which prevents viral entry; and ii) the glial innate immune response, which initiates inflammation and recruits peripheral immune cells to the site of infection (Yadav and Collman, 2009; Yao et al., 2010; Strazza et al., 2011) . The BBB consists of brain endothelial cells bound by cell-cell tight junctions which restrict paracellular movement of compounds from the blood into the CNS parenchyma. The barrier allows facilitated transportation of essential nutrients and small ions while restricting entry of most serum macromolecules (Abbott et al., 2006) . Barrier permeability undergoes rapid, transient changes to accommodate local metabolic demands, but prolonged increases in BBB permeability can lead to an influx of neurotoxic compounds, metabolic imbalances and cell death (Willis and Davis, 2008; Guo and Lo, 2009) .
The importance of the BBB in restricting viral entry into the brain parenchyma has been shown in in vitro studies. Fiala showed that an intact BBB prevented direct entry of cell-free HIV-1 (Fiala et al., 1997) . However, other in vitro studies have shown that the HIV-1 viral protein Tat reduced transendothelial electrical resistance and decreased expression of the tight junction protein occludin in human brain microvascular endothelial cells, indicative of reduced BBB integrity. Morphine exacerbates the effects of HIV-1 Tat on BBB integrity in vitro, but the mechanism is not known (Mahajan et al., 2008) .
Disruption of the BBB is also a feature of HIV-1-associated encephalitis (HIVE) in humans (Strazza et al., 2011) . HIV-1 can be detected in the cerebrospinal fluid of the CNS as early as 15 days post-infection (Tomlinson et al., 1999) . Viral particle entry into the CNS may be due to either direct entry of viral particles or the migration of infected Journal of Neuroimmunology 269 (2014) [44] [45] [46] [47] [48] [49] [50] [51] 
